The regulatory setback occurred when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine, citing critical uncertainties in the company’s new drug application for bitopertin. The agency determined that the provided data lacked sufficient evidence to support approval, triggering the immediate market sell-off. Investors who suffered financial losses during this period are now being invited to join a prospective class action lawsuit to seek recovery of damages.
Disc Medicine Investors Face Investigation Over Misleading Disclosure Claims
A 22% plunge in stock price followed a February 13, 2026, FDA rejection of Disc Medicine’s bitopertin program, prompting the Rosen Law Firm to launch an investigation into potential securities fraud. The firm alleges the company may have misled the public regarding its regulatory filings and business prospects.
Rosen Law Firm, which is handling the inquiry, operates on a contingency fee basis, meaning participants face no upfront costs. Interested shareholders are directed to contact attorney Phillip Kim via the firm’s online portal or by phone to participate in the litigation. While the firm emphasizes its history of securing settlements in securities cases, it notes that prior legal outcomes do not guarantee future results in this specific matter.
Comments (0)
No comments yet. Be the first!